Ankylosing spondylitis (AS) is a chronic inflammatory disorder of unknown aetiology. Unlike
other systemic autoimmune diseases, in AS, the innate immune system has a dominant role …

To update and integrate the recommendations for ankylosing spondylitis and the
recommendations for the use of tumour necrosis factor inhibitors (TNFi) in axial …

Background Secukinumab is an anti–interleukin-17A monoclonal antibody that has been
shown to control the symptoms of ankylosing spondylitis in a phase 2 trial. We conducted …

Objective To provide evidence‐based recommendations for the treatment of patients with
ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). Methods A …

Objectives. For effective health care provision, knowledge of disease prevalence is
paramount. There has been no systematic endeavour to establish continent-based AS …

Objective To investigate the efficacy and safety of ixekizumab in patients with active
radiographic axial spondyloarthritis (SpA) and prior inadequate response to or intolerance of …

2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and
Management of Patients With Thoracic Aortic Disease | Circulation Science Volunteer Warning …

This first update of the ASAS/EULAR recommendations on the management of ankylosing
spondylitis (AS) is based on the original paper, a systematic review of existing …

Objective: To validate and refine two sets of candidate criteria for the classification/diagnosis
of axial spondyloarthritis (SpA). Methods: All Assessment of SpondyloArthritis international …

The aim of Martindale is to provide healthcare professionals with unbiased evaluated
information on drugs and medicines used throughout the world. It therefore has to develop …